Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference

May 28, 2026 7:00 AM EDT

CORAL GABLES, Fla., May 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial Officer, will participate in the Jefferies Global Healthcare Conference being held in New York, NY, from June 2-4, 2026.

Jefferies Global Healthcare Conference Details Format: Fireside Chat Date: Thursday, June 4, 2026 Time: 12:50 PM ET Webcast: Click Here

Management will also be available for one-on-one investor meetings during the conference. Please contact your Jefferies representative to schedule a meeting.

The webcast can also be accessed on the Events page of the Investors section of the Relmada website at https://www.relmada.com/for-investors/ir-calendar . An archived replay will be available for 90 days following the conclusion of the event.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs.

For more information, visit www.relmada.com

Investor Contact: Brian Ritchie LifeSci Advisors [email protected]

Media Inquiries: Corporate Communications media@relmada.com

Source: Relmada Therapeutics

Released May 28, 2026